A detailed history of Bank Of America Corp transactions in Uni Qure N.V. stock. As of the latest transaction made, Bank Of America Corp holds 264,974 shares of QURE stock, worth $1.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
264,974
Previous 314,457 15.74%
Holding current value
$1.5 Million
Previous $1.64 Million 27.4%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.39 - $5.43 $217,230 - $268,692
-49,483 Reduced 15.74%
264,974 $1.19 Million
Q1 2024

May 15, 2024

BUY
$4.82 - $6.93 $190,814 - $274,344
39,588 Added 14.4%
314,457 $1.64 Million
Q4 2023

Feb 14, 2024

SELL
$5.63 - $8.27 $257,443 - $378,162
-45,727 Reduced 14.26%
274,869 $1.86 Million
Q2 2023

Aug 14, 2023

BUY
$11.12 - $22.2 $808,968 - $1.62 Million
72,749 Added 29.35%
320,596 $3.67 Million
Q1 2023

May 12, 2023

BUY
$18.7 - $23.07 $989,342 - $1.22 Million
52,906 Added 27.14%
247,847 $4.99 Million
Q4 2022

Feb 10, 2023

SELL
$18.12 - $27.32 $116,221 - $175,230
-6,414 Reduced 3.19%
194,941 $4.42 Million
Q3 2022

Nov 14, 2022

BUY
$16.98 - $25.54 $2.84 Million - $4.27 Million
167,062 Added 487.16%
201,355 $3.78 Million
Q2 2022

Aug 12, 2022

SELL
$13.15 - $20.45 $1.44 Million - $2.24 Million
-109,374 Reduced 76.13%
34,293 $639,000
Q1 2022

May 16, 2022

SELL
$14.54 - $21.5 $244,286 - $361,221
-16,801 Reduced 10.47%
143,667 $2.6 Million
Q4 2021

Feb 08, 2022

BUY
$20.24 - $36.01 $2.64 Million - $4.7 Million
130,553 Added 436.41%
160,468 $3.33 Million
Q3 2021

Nov 15, 2021

BUY
$26.01 - $38.22 $436,707 - $641,713
16,790 Added 127.92%
29,915 $958,000
Q2 2021

Sep 13, 2021

BUY
$29.97 - $37.17 $393,356 - $487,856
13,125 New
13,125 $404,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $264M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.